Surface Oncology Added to the NASDAQ Biotechnology Index
CAMBRIDGE, Mass., Dec. 21, 2018 (GLOBE NEWSWIRE) — Surface Oncology (NASDAQ: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target […]
Recro Pharma Amends IV Meloxicam License Agreement with Alkermes
Reduces 2019 Cash Requirements by $30 Million; Extends Approval Milestone Payments Over Seven Years MALVERN, Pa., Dec. 21, 2018 (GLOBE […]
Nabriva Therapeutics Announces Closing of up to a $75 million Term Loan
-Financing Strengthens Cash Position Ahead of Two Potential Product Launches in 2019- DUBLIN, Ireland, Dec. 21, 2018 (GLOBE NEWSWIRE) — […]
NanoString to Present at the 37th Annual J.P. Morgan Healthcare Conference
SEATTLE, Dec. 21, 2018 (GLOBE NEWSWIRE) — NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research […]
Foamix Submits New Drug Application to U.S. FDA Seeking Approval of FMX101 in Treatment of Moderate-to-Severe Acne
REHOVOT, Israel and BRIDGEWATER, N.J., Dec. 21, 2018 (GLOBE NEWSWIRE) — Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical stage specialty […]
Iovance Biotherapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
SAN CARLOS, Calif., Dec. 21, 2018 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer […]
TSX News -
Kerr Mines Announces Results of 2018 Annual Meeting
TORONTO, Dec. 21, 2018 (GLOBE NEWSWIRE) — Kerr Mines Inc. (TSX: KER, OTC: KERMF, FRA: 7AZ1) (“Kerr” or the “Company”) […]
MVC Private Equity Fund Completes Sale of Plymouth Rock Energy to ENGIE Resources
PURCHASE, N.Y., Dec. 21, 2018 (GLOBE NEWSWIRE) — MVC Capital, Inc. (NYSE: MVC) (“MVC Capital”), a publicly-traded business development company […]
MVC Capital Declares First Quarter 2019 Dividend
PURCHASE, N.Y., Dec. 21, 2018 (GLOBE NEWSWIRE) — MVC Capital, Inc. (NYSE:MVC), a publicly traded business development company that makes private […]
Loxo Oncology Announces Initiation of Phase 1/2 Clinical Trial for Highly Selective, Non-Covalent BTK Inhibitor, LOXO-305
STAMFORD, Conn., Dec. 21, 2018 (GLOBE NEWSWIRE) — Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company focused on the development and commercialization […]
